Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Di-yu Cui"'
Autor:
Di-yu Cui, Chao Zhang, Yi Chen, Gang-zhen Qian, Wan-xiang Zheng, Zhi-hui Zhang, Yu Zhang, Ping Zhu
Publikováno v:
Lipids in Health and Disease, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background The triglyceride glucose (TyG) index and triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio are recognized as simple non-insulin-based insulin resistance indices. Our study aimed to explore the relationship betw
Externí odkaz:
https://doaj.org/article/d70c1433a24647acbe602fd5ac354874
Autor:
Xiao-Rui Chen1, Di-Yu Cui2, Yun-Qing Chen2 chenyunqing.88@163.com, Tie-Sheng Niu1, Chen, Xiao-Rui Chen Md1 (AUTHOR), Cui, Di-Yu3 (AUTHOR), Chen, Yun-Qing Chen Md PhD2 (AUTHOR), Niu, Tie-Sheng1 (AUTHOR)
Publikováno v:
Clinical & Investigative Medicine. Jun2020, Vol. 43 Issue 2, pE35-E46. 12p.
Publikováno v:
Expert Opinion on Drug Safety. 20:1411-1420
Levosimendan, an inotrope, is widely used in the management of heart failure (HF) and cardiac surgery, but it remains uncertain whether levosimendan can improve renal function in patients with left ventricular dysfunction (LVD).PubMed, Embase, and Co
Publikováno v:
Clinical and Investigative Medicine. 43:E35-46
Purpose: Crush and Culotte techniques have been used increasingly to treat patients with complex unprotected left main coronary artery bifurcation lesions. This article compares published data on these two techniques. Methods: Databases, including Pu
Publikováno v:
Journal of cardiovascular pharmacology. 77(6)
Levosimendan, a calcium sensitizer, exerts inotropic action through improving left ventricular ejection fraction. We noticed that only few clinical studies are published in which the effects of levosimendan on cardiac function are studied by echocard
Publikováno v:
Pacing and clinical electrophysiology : PACEREFERENCES. 44(2)
BACKGROUND Current guidelines did not provide recommendations on indications of an additional implantable cardioverter-defibrillator (ICD) to patients receiving cardiac resynchronization therapy (CRT), and it still remains controversial due to lack o
Background: Current guidelines did not provide recommendations on indications of an additional implantable cardioverter-defibrillator (ICD) to patients receiving cardiac resynchronization therapy (CRT), and it still remains controversial due to lack
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6746404f931f481ccd277eaac3f1a4cd
https://doi.org/10.22541/au.159112166.63733232
https://doi.org/10.22541/au.159112166.63733232
Publikováno v:
Journal of Cardiovascular Pharmacology; Jun2021, Vol. 77 Issue 6, p805-813, 9p